BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

SUPER-REPELLENT BIODEFENCE COATING FINDS HEALTHY APPLICATIONS

March 2 2005 Porton Down, UK – P2i Limited today announced it had started to receive revenues from the first licences granted in the healthcare and life sciences markets for its proprietary super-repellent coatings. P2i’s patented plasma process was originally developed by the Defence Science and Technology Laboratory (Dstl), the UK Ministry of Defence’s research organisation, to protect the armed forces and emergency services personnel against chemical attacks. In a new departure, the P2i coating technology is now proving ideal not only for medical textiles, but also for consumables such as filters, microplates, pipette tips and devices.

 

A P2i-enhanced frit (filter) holding up a droplet of 100% isopropylelalcohol (front left).  An untreated frit is shown behind


Drawing on P2i’s in-depth expertise, the super-repellent coating is applied in specially designed plasma chambers. Using plasma or “energised gas”, P2i’s proprietary super liquid-repellent is deposited in layers only molecules thick over the whole surface of a product. The repellent penetrates deep into fabrics and binds to fibre surfaces at the molecular level creating an invisible protective layer. The result is a coating with a 3x lower surface energy than the benchmark Teflon® (PTFE) and unlike other hydrophobic treatments, it is able to repel 100% isopropylalcohol (IPA) and oils.

According to P2i CEO Quentin Compton-Bishop, this milestone comes as an increasing number of companies in the biomedical sector are starting to realise the new technique’s potential and ease of adoption: “Our first applications have been for the filters used in the wells of DNA forensic testing microplates. The coating achieved is so ultrathin that filter pore size is not affected and remains well within tolerances. Performance-wise, this leads to longer reaction times and thus increased sample recovery. Market reaction has been highly favourable and we are now coating large volumes of filters on a routine basis for customers.”

Currently plasma coating enhancement is performed in P2i’s own facilities. However the company has now demonstrated the robustness and scalability of the process and is able to install plasma coating chambers on customer’s own sites under licence. Compton-Bishop continued: “The overall benefits of our plasma super-repellent coating are highly persuasive – by demonstrably enhancing performance it has a high added value to customers. Adoption rates are fast, scale-up easy and the process is also environmentally friendly. As interest grows we are discovering a wide range of life science and biomedical products that can be treated with the P2i process. I see no reason why the success with filters cannot be repeated with, for example, liquid handling tips, micropipettes, reaction tubes and delivery devices such as inhalers. We also believe that plasma coating is ideal for lab-on-a-chip applications. Finally, woven and non-woven medical textiles for both clothing and woundcare are of course another area which we are investigating in conjunction with our general textile work.”

Interestingly, In addition to enhancing hydrophobic surface properties, the P2i process can also be used to manipulate other effects. Currently P2i’s R&D team are looking at increasing the opposite hydrophilic effect and antimicrobial properties. www.p2ilabs.com


-ENDS-

Notes for editors:
P2i

P2i Ltd. was established in 2004 to commercialise super liquid-repellent treatments developed by the Defence Science and Technology Laboratory (Dstl), the UK Ministry of Defence’s research laboratories (www.dstl.gov.uk). P2i is the exclusive licensee of Dstl’s patents and is a joint venture between Dstl and Porton Capital, a venture firm specialising in civilian applications of military research and technology (www.portoncapital.com). P2i’s plasma technology enables it to deposit materials in layers only molecules thick over the whole surface of a product by means of an ionised gas or “plasma”. This enables the surfaces of the product to be enhanced with a super oleophobic (oilrepellent) and hydrophobic (water-repellent) treatment while leaving the other properties of the product unchanged. So, for example, outdoor wear will have every inch of fabric, zipper and seam protected while leaving the pores of the fabric as open and breathable as they were before and without affecting the feel or drape of the material. Now on a commercial scale, P2i’s enhancement process can be applied to a wide range of products in the textiles, medical, pharmaceutical, electronics and homeland security markets. P2i has the capability also to produce a range of other surface effects, such as hydrophilic, antistatic and fire retardant.

Dstl
Dstl (the Defence Science and Technology Laboratory) is the centre of scientific excellence for the Ministry of Defence, housing one of the largest groups of scientists and engineers in public service in the country. Its 3,000 strong workforce includes some of the nation’s most talented and creative scientists with the brief to ensure that the UK Armed Forces and Government are supported in house by world class scientific advice. Dstl delivers defence research, specialist technical services and the ability to track global technological developments. Its capabilities compare with the best in the world, supporting procurement decisions, defence policy making and operations. For more information visit www.dstl.gov.uk


 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.